LAVAL, Quebec–(BUSINESS WIRE)–Jul 18, 2022–
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously announced syndicated public offering in Canada and the United States (l (‘Offer’) of 16,540,541 common shares at a public price of US$9.25 per common share. Total gross proceeds to the Company were US$153 million, before deduction of underwriting fees and any expenses related to the Offering. Bellus has also granted the underwriters an option exercisable by the underwriters within 30 days of the date of the underwriting agreement to purchase up to 2,481,081 additional common shares of the Company.
The common shares of BELLUS Health are listed on both the Nasdaq Global Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) under the symbol “BLU”. For purposes of TSX approval, the Company relied on the exemption set out in Section 602.1 of the TSX Company Handbook, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq.
The Company intends to use the net proceeds of the Offering primarily to fund BLU-5937 research and development activities, working capital requirements and other general corporate purposes, as set forth in the Supplement (as defined below).
Jefferies, Evercore ISI and RBC Capital Markets acted as joint bookrunners and LifeSci Capital as lead manager.
The Offering was made in Canada pursuant to a prospectus supplement dated July 13, 2022 (the “Supplement”) to the Company’s Amended and Restated Short Form Base Shelf Prospectus dated December 14, 2021 (the A&R basis”) and in the United States. United States pursuant to a registration statement on Form F-10, which became effective automatically upon filing with the United States Securities and Exchange Commission (the “SEC”) on December 14, 2021 (the ” Registration Statement”), containing the Supplement and A&R Base Prospectus filed with the SEC pursuant to the Multijurisdictional Disclosure System established between Canada and the United States.
The Supplement and the accompanying A&R Base Prospectus contain important detailed information about the Offering. The Supplement and the accompanying A&R Base Prospectus may be viewed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Copies of the Supplement and the accompanying Base A&R Prospectus may also be obtained from the Company by telephone at 450-680-4500 or by email at email@example.com or you may request them from, in the United States United, of Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at 877-821-7388 or by email at prospectus—firstname.lastname@example.org, or Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52 nd Street, 35 th Floor, New York, NY 10055, by phone at 888-474-0200 or by email at email@example.com, or RBC Capital Markets, LLC, Attention : Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by phone at 877-822-4089 or by email at firstname.lastname@example.org or, in Canada, Jefferies Securities, Inc., c/o from: General Counsel, 161 Bay Street, Suite 2600, Toronto , ON M5J 2S1 by email at prospectus—email@example.com m, or RBC Dominion Securities Inc., Attention: Distributio n Centre, 180 Wellington Street West, 8th Floor, Toronto, ON M5J 0C2, by phone at 1-416-842-5349 or by email at Distribution.RBCDS@rbccm .com. Prospective investors should read the Supplement and the accompanying A&R Base Shelf Prospectus and other documents filed by the Company before making an investment decision.
No regulatory authority has approved or disapproved of the contents of this press release. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration. or qualification under the securities laws of any such province, state or jurisdiction.
About BELLUS Health
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitivity-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of adults with RCC.
Caution Regarding Forward-Looking Statements
Certain statements contained in this press release, other than statements of fact that are independently verifiable as of the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities laws and regulations, the US Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Such statements, based on management’s current expectations, inherently involve numerous important known and unknown risks, uncertainties and assumptions. In this press release, such forward-looking statements include, but are not limited to, the intended use of proceeds from the Offering. Actual future events may differ from the anticipated events expressed in these forward-looking statements. BELLUS Health believes that the expectations represented by the forward-looking statements are reasonable, but there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on the forward-looking statements included in this press release. These forward-looking statements speak only as of the date they are made, and BELLUS Health is under no obligation and disclaims any intention to publicly update or revise these statements as a result of any new information, future events , circumstances or otherwise, unless required by the applicable provisions. securities laws.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220716005008/en/
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: BELLUS Health Inc.
Copyright BusinessWire 2022.
PUBLISHED: 7/18/2022 1:38 PM / DISK: 7/18/2022 1:38 PM